European Archives - Page 765 of 1559 - European Medical Journal

Non-Factor Therapies in Current Clinical Practice

The 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) took place on 6th–9th February 2024 in…

Sparsentan for treatment of immunoglobulin A nephropathy: Latest study results

In patients with immunoglobulin A nephropathy, use of the endothelin 1 Type A/Ang II subtype 1 receptor antagonist sparsentan can decrease proteinuria and preserve kidney function

EMJ 9.1 2024

Explore this new issue showcasing multidisciplinary healthcare and other pertinent topics, including contraceptive use among females with…

Transitioning Patients From Second- to First-Line Prophylaxis in Hereditary Angioedema

Targetted prophylaxis is recommended for people with HAE, but many remain on attenuated androgens. EMJ spoke to two HAE experts who explain how they help patients to make the switch.

Interview: Emer Kelly

Emer Kelly. Respiratory Consultant and General Physician, St. Vincent’s University Hospital, Dublin, Ireland. I had asthma as a child, so…

Interview: Kiley Whalen

Kiley Whalen. Physician Assistant, Adirondack Rehabilitation Medicine; Master of Science in Physician Assistant Studies at the Center for…

Reviewing Advances in Bone Health

The Bone Health Forum is a sponsored standalone event that unites top experts from the JAPAC region.

Liver Elastography for Methotrexate-Induced Fibrosis

Methotrexate (MTX), an antimetabolite, has a multifarious mechanism of action that most notably includes folate antagonism, effects on…

Surgery and Quality of Life in Cervical Cancer

Cervical cancer is established as a major cause of morbidity and mortality among females globally.1 In Kenya, and other countries with…

Renal Replacement Therapy

End-stage liver disease (ESLD) represents a non-reversible, advanced stage of cirrhosis, where the hepatic architecture is distorted and…